DCM
CMPX icon

Driehaus Capital Management’s Compass Therapeutics CMPX Stock Holding History

Driehaus Capital Management’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-250,000
Closed -$793K – 389
2021
Q4 		$793K Buy
+250,000
New +$829K 0.01% 315

Other funds holding CMPX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Driehaus Capital Management's CMPX Position: Q1 2022 in Review

Driehaus Capital Management sold out of Compass Therapeutics (CMPX) in Q1 2022, closing a stake of 250,000 shares — an estimated $793K sold.

Driehaus Capital Management first reported a position in CMPX in Q4 2021 and held it in 1 quarter. The position peaked at $793K in Q4 2021. 34 funds tracked by Wall St. Rank hold CMPX as of Q1 2022.

  • Driehaus Capital Management reported no remaining Compass Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Driehaus Capital Management sold 250,000 Compass Therapeutics shares in Q1 2022, an estimated $793K.
  • Driehaus Capital Management first reported a position in Compass Therapeutics in Q4 2021 and held it in 1 quarter.
  • Driehaus Capital Management's Compass Therapeutics position peaked at $793K in Q4 2021.
  • 34 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2022.

Based on Driehaus Capital Management's 13F filing for Q1 2022, filed 16 May 2022.